Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine plus escitalopram for obsessive-compulsive disorder
IRCT20191106045356N11Phase 4Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of memantine and escitalopram in obsessive compulsive disorder (OCD), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoints: Severity of OCD symptoms and Cognitive function. Started Jul 2022; status: completed.
02
Drugs
memantineescitalopram
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20191106045356N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191106045356N11.